A Phase I Non-Randomized Study of TP53 Reactivation With Arsenic Trioxide in Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chemotherapy drugs, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic trioxide may be safe, tolerable and/or effective in preventing relapse in patients undergoing allogenic stem cell transplant for AML or MDS.

Start Date01 Nov 2026

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

NCT07856069

/ Not yet recruitingPhase 2IIT

A Prospective, Single-Arm, Open-Label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Arsenic Trioxide Combined With Chemotherapy in Patients With Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma

This prospective, open-label, single-arm, multicenter study will evaluate the efficacy and safety of arsenic trioxide (ATO) combined with chemotherapy in pediatric patients with relapsed or refractory SHH-activated medulloblastoma and/or TP53-mutant medulloblastoma. Eligible participants will be 18 months to 18 years of age.
Participants will receive six cycles of induction chemotherapy containing ATO in combination with etoposide and either cisplatin or cyclophosphamide. The primary outcome is the objective response rate (ORR), defined as the proportion of participants achieving a complete response or partial response, assessed according to the Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria by an independent review committee.
Secondary outcomes include overall survival, progression-free survival, and treatment-related safety, including adverse events and serious adverse events. A total of 78 participants are planned for enrollment.

Start Date01 Oct 2026

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

NCT07504458

/ RecruitingPhase 3

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Start Date08 Jun 2026

Sponsor / Collaborator

Quetzal Therapeutics, LLC.

100 Clinical Results associated with Arsenic Trioxide

100 Translational Medicine associated with Arsenic Trioxide

100 Patents (Medical) associated with Arsenic Trioxide

3,379

Literatures (Medical) associated with Arsenic Trioxide

31 Dec 2026·ANNALS OF MEDICINE

Acute leukemia during pregnancy: a single center experience with 23 cases, 2012–2022 and literature review

Review

Author: Chen, Cong ; Zhao, Xie-Lan ; Guo, Jiamin ; Liu, Yi ; Gai, Dongzheng ; Fu, Xiao ; Liu, Wei ; Rosen, Steven T. ; Chen, Fangping ; Zhang, Kai-Xuan

BACKGROUND AND OBJECTIVE:

Acute Leukemia (AL) diagnosed during pregnancy is uncommon, and the management of AL complicated by pregnancy is a poorly studied area that faces a therapeutic dilemma.

METHOD:

23 cases diagnosed with AL during pregnancy were collected from our center between 2012 and 2022. Additionally, we summarized 17 clinical studies on AL diagnosed during pregnancy.

RESULT:

Sixteen AML and seven ALL patients were diagnosed during pregnancy in our center; most patients diagnosed during the first or second trimester tended to receive chemotherapy after abortion. All patients diagnosed during the third trimester opted to defer therapy until after delivery. The rate of overall response rate (ORR) was 77.3%, which was found to be similar to that of the general population. A Short delay in initiating anti-leukemia treatment is not associated with a negative impact on prognosis. We conducted a meta-analysis of the literature, and the summary relative complete remission (CR) rate was 76.9% (95%CI 69.1-84.6%) (Random Effects Model I^2 = 66%, p <0.001). We included four Chinese studies comprising 135 participants for further analysis. For non-M3 AL patients, CR rate of the chemotherapy-first cohort was 63.6%, compared with 68.6% in the treatment-after-delivery or abortion cohort (p = 0.657). For M3 patients, the rate was 100 and 83.3%, respectively (p < 0.001).

CONCLUSION:

Our findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using ATRA-based regimens without arsenic trioxide (in the second and third trimester) or standard chemotherapy (in the second trimester) may be considered a treatment option.

31 Dec 2026·Journal of the International Society of Sports Nutrition

Association between usual protein intake and muscle function in older U.S. adults: a target-trial emulation using NHANES 2011–2018

Article

Author: Ling, Yang ; Riaz, Muhammad ; Hou, Ming-Xuan ; Rahman, Najm Ur

BACKGROUND:

The link between long-term protein intake and muscle performance in older adults has been hard to define, partly because most studies rely on short dietary windows and are vulnerable to confounding and measurement noise. In this work, we attempted to estimate the usual protein intake and functional limitation among U.S. adults aged ≥ 60 years using a target-trial emulation framework with overlap weighting and semiparametric estimators.

METHODS:

Data were drawn from four NHANES survey cycles (2011-2018), including 5,736 adults aged ≥ 60 years with complete exposure, outcome, and covariate data. Usual protein intake (g/kg/day) was derived from available 24-hour recalls to approximate habitual intake. The primary outcome was PFQ-defined mobility limitation across cycles; grip strength (2011-2014) was analyzed separately as a secondary outcome. Causal contrasts across predefined intake categories (<0.8, 0.8- < 1.0, 1.0- < 1.2, ≥1.2 g/kg/day) were evaluated using covariate-balancing propensity score overlap weighting (ATO estimand) followed by marginal structural models. Doubly robust sensitivity analyses were conducted using augmented inverse probability weighting and targeted maximum likelihood estimation with generalized linear models. Simulation extrapolation (SIMEX) was applied to assess potential bias from dietary measurement error. Exploratory analyses evaluated hs-CRP as a potential mediator and tested effect modification by vitamin D status and physical activity.

RESULTS:

Mean usual protein intake was 0.93 g/kg/day, and approximately 42% of participants consumed at least 0.8 g/kg/day, the current Recommended Dietary Allowance (RDA) for the general adult population. In the prespecified overlap-weighted marginal structural model (ATO estimand), higher intake was associated with lower odds of mobility limitation, although the primary contrast comparing ≥ 1.2 versus < 0.8 g/kg/day was modest and not statistically significant (OR 0.89, 95% CI 0.54-1.47). A doubly robust binary contrast yielded a -6.6 percentage-point difference in predicted limitation (95% CI -25.8 to 12.7), consistent in direction but imprecise. In cycle-specific analyses, the inverse association was more pronounced in 2015-2018 (OR 0.80, 95% CI 0.65-0.98). Spline models suggested a steeper decline in predicted limitation below approximately 1.0-1.1 g/kg/day, with a flatter trajectory at higher intakes. Exploratory mediation models indicated a potential indirect component through hs-CRP, though these estimates were not overlap-weighted and should be interpreted cautiously.

CONCLUSIONS:

Higher usual protein intake was directionally associated with lower odds of mobility limitation among older U.S. adults within a target trial emulation framework, although the primary overlap-weighted estimates were modest and imprecise. Evidence of nonlinearity suggests that intakes near 1.0-1.1 g/kg/day may mark a range where predicted limitation declines more steeply, but uncertainty increases at higher intake levels. Given the cross-sectional design and residual potential for confounding, these findings should be interpreted cautiously. Prospective studies are needed to determine whether sustained protein intake in this range meaningfully preserves functional capacity over time.

01 Dec 2026·TOXICOLOGY

Co-exposure to fluoride and arsenic induces endoplasmic reticulum stress in C2C12 myoblasts and MC3T3 preosteoblasts

Article

Author: Bhat K, Deepika ; Nagendra, Apoorva H ; Shenoy P, Sudheer ; Pinto, Joel Rimson ; Bose, Bipasha

Environmental exposure to fluoride and arsenic is a major public health concern in many regions worldwide. Although both toxicants are known to impair skeletal development, the cellular mechanisms underlying their combined effects on skeletal muscle and bone cells remain poorly understood. This study investigated the impact of sodium fluoride (NaF) and arsenic trioxide (As₂O₃) co-exposure, for the first time, in C2C12 myoblasts (at 0.14 mM NaF + 2.4 µM As₂O₃) and MC3T3 preosteoblasts (at 0.64 mM NaF + 13 µM As₂O₃). Co-exposure significantly reduced cell proliferation and decreased the expression of the lineage specific transcription factors such as MYOD and RUNX2 in C2C12 and MC3T3 cells, respectively. Both individual and combined treatments increased ROS production, with co-exposure producing the highest oxidative stress. Further, fluoride and arsenic co-exposure exerted its effects by inducing endoplasmic reticulum stress in both cell types which was witnessed by the activation of the unfolded protein response (UPR) pathways. Specifically, in C2C12 myoblasts, co-exposure predominantly activated the PERK-Atf4-Chop pathway while suppressing IRE1α-Xbp1 expression, indicating unresolved ER stress. In contrast, MC3T3 preosteoblasts activated both PERK-Atf4-Chop and IRE1α-Xbp1 pathways, suggesting engagement of adaptive ER stress mechanisms. Collectively, these findings demonstrate that fluoride and arsenic co-exposure disrupts cellular homeostasis by inducing ER stress in both myoblasts and preosteoblasts. The differences in activation of different UPR pathways suggests C2C12 myoblasts to be more susceptible to fluoride and arsenic co-exposure compared to MC3T3 preosteoblasts.

186

News (Medical) associated with Arsenic Trioxide

09 Sep 2026

·www.biospace.com

Quetzal Therapeutics Appoints Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer

CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, including hematologic malignancies, today announced the appointment of Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer. “Harindra is an accomplished regulatory leader who has successfully guided the development of novel therapies through complex regulatory pathways, including multiple new molecular entity approvals and label expansions across a broad range of therapeutic areas,” said Usman Ahmed, Chief Executive Officer and Chairman of Quetzal Therapeutics. “As we continue to advance QTX-2101, Harindra’s experience will be invaluable in shaping a development strategy and defining the most optimal path toward potential registration.” “I am excited to join Quetzal at a pivotal stage in the development of QTX-2101 and the broader pipeline,” said Dr. Abeysinghe. “QTX-2101 aims to build on a therapeutic drug already well established in APL, and its potential to transform patients’ lives in how that therapy is administered is what I find compelling. I look forward to building the regulatory and quality foundation for the program as it advances and shaping Quetzal’s global regulatory strategy.” Dr. Abeysinghe joins Quetzal following a more than 25-year career at Johnson & Johnson Research & Development, where he held positions of increasing responsibility across Global Regulatory Affairs and drug development. Most recently, Dr. Abeysinghe served as Senior Vice President and Head of Regulatory for Oncology, where he led regulatory strategy for their oncology portfolio. During his tenure in Oncology, he oversaw and led the regulatory team in achieving several new drug approvals and line extensions and indications across both heme malignancies and solid tumors. Harindra has broad experience in drug development, having worked across numerous therapeutic areas including Oncology, Vaccines, Neuroscience, Immunology, Infectious diseases and Diagnostics. Dr. Abeysinghe also has regional experience having also served as Vice President and Head for Regulatory Affairs based in Singapore. Dr. Abeysinghe holds a Ph.D. in Oncology from the Department of Pathology and Laboratory Medicine at the University of Rochester, where his doctoral research focused on the identification of a novel tumor suppressor gene for ovarian cancer. He also holds an M.S. from the University of Rochester and a B.S. in Biochemistry and Music from Beloit College. About Quetzal Therapeutics Quetzal Therapeutics is a biopharmaceutical company dedicated to developing treatments for rare diseases, including hematologic malignancies. The company’s lead product, QTX-2101, is a novel, investigational approach for treating patients with Acute Promyelocytic Leukemia (APL). Quetzal is also advancing QTX-2102, a pre-clinical, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. QTX-2101 is an investigational, oral capsule formulation of arsenic trioxide. It is being evaluated as a potential oral alternative to intravenous arsenic trioxide. QTX-2101 has been granted Orphan Drug Designation by the U.S. FDA and the European Commission, as well as FDA Fast Track designation. QTX-2101 has not been approved by any regulatory authority, and its safety and efficacy have not been established. This press release contains forward-looking statements reflecting current expectations for ongoing development, which may evolve over time. For more information, please visit: Contacts: Investors: Ami Bavishi or Nick Colangelo Gilmartin Group LLC quetzaltx@gilmartinir.com Media: info@quetzaltx.com

Orphan DrugExecutive ChangeFast Track

11 Jun 2026

·www.biospace.com

Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia

CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company’s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL. "Dosing the first patient in QUATRO-APL is an important clinical development milestone for Quetzal," said Usman Ahmed, Chief Executive Officer and Chairman of Quetzal Therapeutics. "We look forward to continued enrollment and to working with our investigators, clinical sites, and partners as the trial progresses." "Current standard-of-care regimens for APL require a significant number of intravenous infusions over the course of therapy, which can be burdensome for patients and healthcare systems," said Shaad Abedin, M.D., Chief Medical Officer of Quetzal Therapeutics. "QUATRO-APL is designed to evaluate whether an oral formulation of arsenic trioxide can offer a potential alternative to intravenous administration. We are grateful to the investigators, site teams, and partners whose commitment made this milestone possible." Quetzal Therapeutics expects continued site activation and patient enrollment across the United States and Europe as the global Phase 3 program advances and plans to provide additional updates on study progress as enrollment continues. About the QUATRO-APL Trial QUATRO-APL (QTX-2101-301) is a pivotal, open-label Phase 3 clinical study evaluating the efficacy, safety, and pharmacokinetics of QTX-2101, an oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), in adult patients with newly diagnosed, low-risk acute promyelocytic leukemia. The comparator arm is intravenous arsenic trioxide plus ATRA. Additional information is available at ClinicalTrials.gov (NCT07504458) and the EU Clinical Trials Information System (2025-524810-28-00). About Acute Promyelocytic Leukemia APL is a rare and aggressive subtype of acute myeloid leukemia, accounting for approximately 10-15% of all AML cases. It is defined by the PML-RARA gene fusion and is associated with severe bleeding complications and rapid disease progression if untreated. While advances in therapy have transformed outcomes, current treatments often require patients to undergo a large number of lengthy intravenous infusions over the course of therapy. This relentless treatment schedule can disrupt daily life and place a significant burden on both patients and their support networks. There remains a clear need for innovative and more accessible therapies. About Quetzal Therapeutics Quetzal Therapeutics is a biopharmaceutical company dedicated to developing treatment for rare diseases, including hematologic malignancies. The company’s lead product is QTX-2101, a novel, investigational approach for treating patients with APL. Quetzal is also advancing QTX-2102, a pre-clinical, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. QTX-2101 is an investigational, oral capsule formulation of arsenic trioxide . It is being evaluated as a potential oral alternative to intravenous arsenic trioxide. QTX-2101 has been granted Orphan Drug Designation by the U.S. FDA and the European Commission, as well as FDA Fast Track designation. QTX-2101 has not been approved by any regulatory authority, and its safety and efficacy have not been established. This press release contains forward-looking statements reflecting current expectations for ongoing development, which may evolve over time. For more information, please visit: Media Contact: info@quetzaltx.com

30 Jan 2026

·www.biospace.com

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101 , the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute promyelocytic leukemia (APL) . QTX-2101 is an oral capsule formulation of arsenic trioxide developed with the goal of addressing limitations associated with intravenous administration, including the need for frequent clinic visits. The potential for QTX-2101 to simplify treatment administration while maintaining precise dosing and stability is under investigation. QTX-2101 is currently being evaluated in a global, multicenter, randomized, controlled Phase III clinical trial comparing the investigational oral capsule to standard-of-care therapy in patients with newly diagnosed APL. The trial builds on pharmacokinetic and safety data from prior Phase I studies conducted in the United States. The Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies for serious conditions, underscoring the severity of APL and the continued unmet medical need despite an effective standard of care therapy. This designation allows for more frequent interaction with the FDA as the clinical development of QTX-2101 progresses, and may enable a more efficient registration filing upon positive data. The therapy remains investigational, and its safety and efficacy have not yet been established. Fast Track designation does not change the standards for approval and does not guarantee that QTX-2101 will receive FDA approval. About Acute Promyelocytic Leukemia (APL) APL is a rare and aggressive subtype of acute myeloid leukemia, accounting for approximately 10-15% of all AML cases. It is defined by the PML-RARA gene fusion and is associated with severe bleeding complications and rapid disease progression if untreated. While advances in therapy have transformed outcomes, current treatments often require patients to undergo a large number of lengthy intravenous infusions over the course of therapy. This relentless treatment schedule can disrupt daily life and place a significant burden on both patients and their support networks. There remains a clear need for innovative and more accessible therapies. About Quetzal Therapeutics Quetzal Therapeutics is a biopharmaceutical company dedicated to developing treatment for rare diseases, including hematologic malignancies. The company’s lead product is QTX-2101, a novel approach for treating patients with APL. Quetzal is also advancing QTX-2102, a pre-clinical, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release contains forward-looking statements reflecting current expectations for ongoing development, which may evolve over time. For more information, please visit: Media Contact: info@quetzaltx.com

Fast TrackPhase 3Phase 1

100 Deals associated with Arsenic Trioxide

External Link

KEGG	Wiki	ATC	Drug Bank
D02106	Arsenic Trioxide	L01XX27	DB01169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	United States	Cephalon LLC	25 Sep 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	United States	Cephalon LLC	01 Oct 2007
Acute Myeloid Leukemia	Phase 3	Canada	Cephalon LLC	01 Oct 2007
Systemic Lupus Erythematosus	Phase 2	France	Medsenic SAS	01 Jul 2013
Small Cell Carcinoma	Phase 2	United States	Teva Pharmaceuticals USA, Inc.	01 Aug 2011
Small Cell Carcinoma	Phase 2	United States	Cephalon LLC	01 Aug 2011
Small Cell Lung Cancer	Phase 2	United States	Cephalon LLC	01 Aug 2011
Small Cell Lung Cancer	Phase 2	United States	Teva Pharmaceuticals USA, Inc.	01 Aug 2011
Metastatic endometrial cancer	Phase 2	United States	Cephalon LLC	01 Mar 2010
uterus adenocarcinoma	Phase 2	United States	Cephalon LLC	01 Mar 2010
Glioma	Phase 2	United States	Cephalon LLC	01 May 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Acute Promyelocytic Leukemia	1,134	ATRA+ATO combined with gemtuzumab ozogamicin (GO) or low-dose anthracycline	zogkjyoevm(kocnryrgga) = zmwsyfudwb gxweqilaoe (brbnqpiccz, 4.7 - 15.9) View more	Positive	29 May 2026
				ATRA-based therapy with ≥3 anthracycline doses	zogkjyoevm(kocnryrgga) = nidvklaqkq gxweqilaoe (brbnqpiccz, 6.8 - 15.5) View more
JPRN-jRCTs041190101 (APL219R, EHA2026)	Phase 2	CD33-positive	39	Tamibarotene+Arsenic trioxide+Gemtuzumab ozogamicin	dfbdlayxsh(uybsfftsev) = hksjhrqpkh gglpbmwamn (cldkqghtsk ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Acute Promyelocytic Leukemia	72	ATRA+ATO	dzzdeaicoy(beehlmucmi) = vjzpdncleh ayhcnguzra (jxockoniyd ) View more	Positive	12 May 2026
APOLLO (EHA2026)	Phase 3	Acute Promyelocytic Leukemia	133	all-trans retinoic acid and arsenic trioxide (ATRA/ATO)	cyzasdaqgo(pemvqdswbe) = lgridoksie kuwgjbkpkn (qbinfsuhgy, 73 - 94) View more	Superior	12 May 2026
				ATRA plus idarubicin (AIDA)	cyzasdaqgo(pemvqdswbe) = mveochvozv kuwgjbkpkn (qbinfsuhgy, 52 - 79) View more
ASH2025	Not Applicable	Acute Promyelocytic Leukemia	64	ATRA + arsenic-based regimens	empanxgjmz(ojtxlyiejy) = yadxtgucgv wcidokigcm (wqqxuzidzw ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Promyelocytic Leukemia	26	ATRA+ATO/RIF+venetoclax	rhmazqvcqb(mfyrffehgw) = ntfugbdyqo jveukhucva (sjpmowbhzs ) View more	Positive	06 Dec 2025
NCT02688140 (APOLLO, Pubmed \| J Clin Oncol)	Phase 3	Acute Promyelocytic Leukemia First line	133	Arsenic Trioxide + All-Trans Retinoic Acid + Idarubicin	algrbybbpc(exmtxtdnlb) = etyzqlviai iweffiydpc (sgcnafipks )	Positive	10 Oct 2025
				Standard All-Trans Retinoic Acid + Anthracycline-Based Chemotherapy	algrbybbpc(exmtxtdnlb) = zkakftvxln iweffiydpc (sgcnafipks )
PF538 (EHA2025)	Not Applicable	Acute Promyelocytic Leukemia	156	Standard-dose ATO group	tvsjkuwhic(xaybdwufok) = yuahahqezo cnclgtzwdx (fviajcblyt ) View more	-	14 May 2025
				Low-dose ATO group	tvsjkuwhic(xaybdwufok) = hbhvenmvvk cnclgtzwdx (fviajcblyt ) View more
ASH2024	Not Applicable	Acute Promyelocytic Leukemia	-	Standard-dose ATO (10mg IV daily for 28 days)	hruhasxiup(hwdmtonmhr) = Patients receiving ATO treatment have a high rate of adverse events in both groups, reducing the total ATO dosage at induction treatment may reduce the adverse event rate and help patients achieve the same long-term survival. snqoisoiub (reogdxdfkg )	-	09 Dec 2024
				Low-dose ATO (10mg IV daily for less than 28 days)
ESMO_ASIA2024	Not Applicable	Acute Promyelocytic Leukemia Consolidation	19	ATRA, ATO, DNR	vhehwsjams(dtwpvtbuxj) = 6 patients ujhutckmcb (vyxuqbnvjs ) View more	Positive	07 Dec 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis